Education
About Us
Working with TipRanks
Follow Us
Spero Therapeutics Inc (SPRO)
NASDAQ:SPRO
SPRO Stock Chart & Stats
$2.37
-$0.03(-2.91%)
At close: 4:00 PM EST
$2.37
-$0.03(-2.91%)
Day’s Range― - ―
52-Week Range$0.51 - $3.22
Previous CloseN/A
Volume61.58K
Average Volume (3M)214.84K
Market Cap
$138.03M
Enterprise Value$80.37M
Total Cash (Recent Filing)$48.62M
Total Debt (Recent Filing)$3.35M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Mar 26, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding56,339,294
10 Day Avg. Volume192,405
30 Day Avg. Volume214,836
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)1.16
P/FCF Ratio-2.37
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue2.25
Enterprise Value/Gross Profit-1.11
Enterprise Value/Ebitda-1.78
Forecast
1Y Price Target
$4.00Price Target Upside68.78% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$800.00K
Bulls Say, Bears Say
Bulls Say
Clinical Trial EfficacyA late-stage trial met its primary endpoint and was stopped early for efficacy, strengthening the likelihood of regulatory approval and speeding the route to market.
Cost Reduction And Cash RunwayCompletion of a major trial reduced research and development spending and conserved cash, supporting a longer operational runway and lowering near-term financing pressure.
Partnership MilestonesLicensing arrangement with GSK includes substantial development and commercial milestones plus tiered royalties, creating potential meaningful future revenue if the partner advances the program.
Bears Say
Concentration And Partner Execution RiskHeavy dependence on a single partnered program and on the partner's regulatory and commercial decisions raises execution risk if the partner changes timelines or strategy.
Milestone Payment ReductionEarly stoppage of the trial resulted in a prorated milestone payment instead of the full expected amount, reducing near-term cash inflows tied to the partnership.
Ongoing Operating LossesReported net losses highlight continued operating shortfalls that could necessitate additional funding or equity issuance if revenue growth is delayed.
Spero Therapeutics News
SPRO FAQ
What was Spero Therapeutics Inc’s price range in the past 12 months?
Spero Therapeutics Inc lowest stock price was $0.51 and its highest was $3.22 in the past 12 months.
What is Spero Therapeutics Inc’s market cap?
Spero Therapeutics Inc’s market cap is $138.03M.
When is Spero Therapeutics Inc’s upcoming earnings report date?
Spero Therapeutics Inc’s upcoming earnings report date is Mar 26, 2026 which is in 56 days.
How were Spero Therapeutics Inc’s earnings last quarter?
Spero Therapeutics Inc released its earnings results on Nov 13, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.12.
Is Spero Therapeutics Inc overvalued?
According to Wall Street analysts Spero Therapeutics Inc’s price is currently Undervalued.
Does Spero Therapeutics Inc pay dividends?
Spero Therapeutics Inc pays a Quarterly dividend of $0.015 which represents an annual dividend yield of N/A. See more information on Spero Therapeutics Inc dividends here
What is Spero Therapeutics Inc’s EPS estimate?
Spero Therapeutics Inc’s EPS estimate is -0.2.
How many shares outstanding does Spero Therapeutics Inc have?
Spero Therapeutics Inc has 56,339,294 shares outstanding.
What happened to Spero Therapeutics Inc’s price movement after its last earnings report?
Spero Therapeutics Inc reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went down -1.23%.
Which hedge fund is a major shareholder of Spero Therapeutics Inc?
Currently, no hedge funds are holding shares in SPRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spero Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.00 (68.78% Upside)
$4.00 (68.78% Upside)
Blogger Sentiment
Bullish
SPRO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 22.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $95.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
182.58%
12-Months-Change
Fundamentals
Return on Equity
-95.29%
Trailing 12-Months
Asset Growth
-59.92%
Trailing 12-Months
Company Description
Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
SPRO Stock 12 Month Forecast
Average Price Target
$4.00
▲(68.78% Upside)
Technical Analysis
Milestone Pharmaceuticals
―
Korro Bio
―
Connect Biopharma Holdings
―
Tenaya Therapeutics
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
8.15% Insiders
4.07% Mutual Funds
0.18% Other Institutional Investors
84.41% Public Companies and
Individual Investors